Get the Stockscreener App
97.12
0.69%
-0.67
After Hours:
96.61
-0.51
-0.53%
Monopar Therapeutics Inc stock is traded at $97.12, with a volume of 103.87K.
It is down -0.69% in the last 24 hours and up +63.28% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
See More
Previous Close:
$97.79
Open:
$98.33
24h Volume:
103.87K
Relative Volume:
0.61
Market Cap:
$650.61M
Revenue:
-
Net Income/Loss:
$-14.99M
P/E Ratio:
-47.00
EPS:
-2.0665
Net Cash Flow:
$-10.01M
1W Performance:
+2.71%
1M Performance:
+63.28%
6M Performance:
+59.04%
1Y Performance:
+167.92%
1-Day Range:
$96.61
$101.09
1-Week Range:
$91.90
$101.09
52-Week Range:
$29.18
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
97.12 | 620.27M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar Therapeutics price target raised to $117 from $104 at BTIG - TipRanks
MNPR Maintained by BTIG -- Price Target Raised to $117 - GuruFocus
Form 4 Monopar Therapeutics Inc For: 30 June By Investing.com - Investing.com Canada
Monopar Therapeutics (MNPR) director granted 1,284 stock options - Stock Titan
Monopar Therapeutics (MNPR) director Nicole Sweeny files initial Form 3 - Stock Titan
Monopar gets rare pediatric disease tag for Wilson treatment - Investing.com UK
Monopar Therapeutics (MNPR) Receives FDA Rare Pediatric Disease Designation - GuruFocus
Monopar Therapeutics Inc. Granted FDA Rare Pediatric Disease Designation – Official SEC 8-K Filing June 30, 2026 - Minichart
Monopar Wins FDA Rare Pediatric Disease Designation - TipRanks
Monopar stock jumps after FDA rare pediatric disease tag By Investing.com - Investing.com India
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease - The Manila Times
FDA grants Rare Pediatric Disease designation to Monopar (MNPR) Wilson disease drug ALXN1840 - Stock Titan
FDA rare pediatric disease tag could speed ALXN1840’s path for Wilson disease - Stock Titan
BTIG raises Monopar Therapeutics price target on regulatory outlook - Investing.com
BTIG raises Monopar Therapeutics price target on regulatory outlook By Investing.com - Investing.com Canada
+8.47% for Monopar Therapeutics stock as buyers push price above key averages - Traders Union
Monopar Therapeutics Inc Actuals & Estimates (NASDAQ:MNPR) - TradingView
H.C. Wainwright reiterates Monopar stock rating on trial data By Investing.com - Investing.com India
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 2000 Value Benchmark - marketscreener.com
H.C. Wainwright reiterates Monopar stock rating on trial data - Investing.com UK
Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index - marketscreener.com
MNPR Reiterates by HC Wainwright & Co. -- Price Target Maintained at $105 - GuruFocus
Monopar Therapeutics Insiders Make Handsome Sum Selling Stock At US$67.15 Per Share - simplywall.st
Price to earnings forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Price to book forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 2500 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Enterprise value to EBITDA forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Enterprise value to revenue forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Enterprise value to revenue forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Price to sales forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Price to earnings forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Monopar plans mid-2026 NDA filing for Wilson disease drug - Investing.com UK
MNPR Forecast — Price Target — Prediction for 2027 - TradingView
Monopar Highlights Positive Phase 3 Wilson Disease Data - TipRanks
Monopar Therapeutics (MNPR) to Present New Data on ALXN1840 at E - GuruFocus
Monopar Presents Phase 3 FoCus Data Showing Neurologic and Global Benefit with ALXN1840 - TradingView
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease - The Manila Times
ALXN1840 Phase 3 data back NDA plan for Wilson disease, Monopar (NASDAQ: MNPR) - Stock Titan
Monopar Therapeutics Inc Actuals & Estimates (LS:A40JML) - TradingView
Monopar Therapeutics Inc Actuals & Estimates (DUS:1IY0) - TradingView
A40JML Forecast — Price Target — Prediction for 2027 - TradingView
Monopar plans mid-2026 NDA filing for Wilson disease drug By Investing.com - Investing.com South Africa
1IY0 Forecast — Price Target — Prediction for 2027 - TradingView
NDA submission progress for ALXN1840 in Wilson disease sends Monopar Therapeutics stock up 7.61% - Traders Union
Monopar Therapeutics Inc Cash Flow – DUS:1IY0 - TradingView
Monopar Therapeutics Inc (MNPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Monopar Therapeutics Surges 18%: Biotech Momentum Builds Past Key ResistanceMFI Divergence - dars.gov.et
Near-term momentum pushes Monopar Therapeutics stock up 7.19% - Traders Union
Monopar Therapeutics shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
Monopar Therapeutics shareholders approve all proposals at annual meeting - Investing.com
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):